Risk Factors in Tachycardiomyopathy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-10-11

Study Completion Date

2030-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Decision between rate control and rhythm control can be a challenge in clinical practice. While there is some guiding evidence, we still lack a comprehensive insight into different subgroups of patients that will benefit from a rhythm control treatment.

EMPATHY is a prospective clinical study in patients presenting with heart failure and a tachyarrhythmic rhythm disturbance. Biomarkers, routinely obtained results from clinical examinations, and results from endomyocardial biopsies shall be evaluated to identify patients which have better outcome from a rhythm control strategy by ablation therapy or, if contraindicated by pharmacological rhythm control.

This study is designed to identifying risk factors and subgroups profiting from rhythm restoration and therefore improve current therapeutic approaches and the rate of recurrence-free survival.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ventricular Tachycardia Mechanisms

NCT05478213

Ventricular Tachycardia

RECRUITING NA

Hypertrophic Cardiomyopathy Pilot Study

NCT02806479

Hypertrophic Cardiomyopathy Coronary Artery Disease

COMPLETED

Qualitative Analysis of Photoplethysmography Waveforms for the Detection of Cardiac Arrhythmias

NCT04374344

Cardiac Arrhythmia

COMPLETED

The Use of Dual Chamber ICD With Special Programmed Features to Lower the Risk of Inappropriate Shock

NCT00787800

Ventricular Tachycardia Ventricular Fibrillation Atrial Fibrillation +1 more

COMPLETED PHASE4

Effects of Atrial Rate-adaptive Pacing on Exercise Capacity in Patients With Chronic Heart Failure Complicated by Chronotropic Incompetence

NCT01016431

Heart Failure Exercise Tolerance

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation Atrial Flutter Ventricular Premature Complexes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

tachycardiomyopathy

Sustained heart rate of over 100 bpm, exclusion of other causes of congestive heart failure including significant valvular disease and coronary artery stenosis over 50%, and partial or complete recovery of left ventricular function after restoration of sinus rhythm or rate control and characteristic histological findings.

No interventions assigned to this group

dilated cardiomyopathy

Patients with dilated cardiomyopathy according to the 2016 ESC (European Heart Association) Guidelines for the diagnosis and treatment of acute and chronic heart failure.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* newly diagnosed left ventricular ejection fraction ≤ 50%
* endomyocardial biopsy available
* tachycardic rhythm disturbance with a rhythm control strategy planned for tachycardic atrial fibrillation or flutter (≥100/min) or more than 10000 ventricular premature beats in 24 hours

Exclusion Criteria

* age \<18 years
* patient unable or unwilling to give informed consent
* coronary artery stenosis \>50%
* relevant valvular disease
* simultaneous contraindications against amiodarone treatment and pulmonary vein isolation/ablation therapy
* present or suspected alcohol/drug dependency will result in exclusion from the study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No